Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Woo-Shik | - |
dc.contributor.author | Kim, Hyun Soo | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Park, Ijong Chun | - |
dc.contributor.author | Yoo, Han-Wook | - |
dc.contributor.author | Takenaka, Toshihiro | - |
dc.contributor.author | Tei, Chuwa | - |
dc.date.accessioned | 2021-08-02T12:27:58Z | - |
dc.date.available | 2021-08-02T12:27:58Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2019-02 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/15095 | - |
dc.description.abstract | Background Fabry disease is an X-linked recessive disorder caused by deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A). Previous studies identified many cases of Fabry disease among men with left ventricular hypertrophy (LVH). The purpose of this study was to define the frequency of Fabry disease among Korean men with LVH. Methods In this national prospective multicenter study, we screened Fabry disease in men with LVH on echocardiography. The criterion for LVH diagnosis was a maximum LV wall thickness 13 mm or greater. We screened 988 men with LVH for plasma α-Gal A activity. In patients with low α-Gal A activity (< 3 nmol/hr/mL), we searched for mutations in the α-galactosidase gene. Results In seven men, α-Gal A activity was low. Three had previously identified mutations; Gly328Arg, Arg301Gln, and His46Arg. Two unrelated men had the E66Q variant associated with functional polymorphism. In two patients, we did not detect GLA mutations, although α-Gal A activity was low on repeated assessment. Conclusion We identified three patients (0.3%) with Fabry disease among unselected Korean men with LVH. Although the prevalence of Fabry disease was low in our study, early treatment of Fabry disease can result in a good prognosis. Therefore, in men with unexplained LVH, differential diagnosis of Fabry disease should be considered. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.title | Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Jinho | - |
dc.identifier.doi | 10.3346/jkms.2019.34.e63 | - |
dc.identifier.scopusid | 2-s2.0-85062167458 | - |
dc.identifier.wosid | 000459545300005 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.34, no.7 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 34 | - |
dc.citation.number | 7 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002437731 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ALPHA-GALACTOSIDASE | - |
dc.subject.keywordPlus | REPLACEMENT THERAPY | - |
dc.subject.keywordPlus | CARDIOMYOPATHY | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordAuthor | Fabry Disease | - |
dc.subject.keywordAuthor | Left Ventricular Hypertrophy | - |
dc.subject.keywordAuthor | Korean Men | - |
dc.identifier.url | https://jkms.org/DOIx.php?id=10.3346/jkms.2019.34.e63 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.